Severe systemic inflammatory response syndrome in a patient with adult onset Still`s disease treated with the anti-IL1 drug anakinra: a case report

CER3148
2007 Vol.25, N°5
PI 0758, PF 0759
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 18078628 [PubMed]

Abstract

Interleukin 1 (IL1) plays an important role in adult onset Still`s disease. Anakinra (Kineret®), a recombinant IL1 Receptor Antagonist (IL 1 RA) was therefore recently proposed in adult onset Still`s disease with great efficacy. Anakinra appeared to be well tolerated and safe. The case of a patient with refractory adult onset Still`s disease who experienced a Systemic Inflammatory Response Syndrome and Adult Respiratory Distress Syndrome requiring intensive care unit hospitalization 10 days after the introduction of anakinra is reported.